A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety,
tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients
with schizophrenia.